Such minor cell populations in otherwise monoclonal DMBA/TPA–derived papillomas have been recently described and shown to lack the activating mutation in Hras, the predominant proto-oncogene activated in DMBA/TPA–induced tumors (Reeves et al, 2018). The gene discussed is HRAS; the disease is papilloma.